The faces of personalized medicine: a framework for understanding its meaning and scope.

The objective of this article was to provide a framework for understanding the different definitions of the term "personalized medicine." The term personalized medicine is used regularly but interpreted in different ways. This article approaches the term by starting with a broad view of clinical medicine, where three components can be distinguished: the questions (e.g., what is the diagnosis?), the methods used to answer them (e.g., a test), and the available actions (e.g., to give or not give a particular drug). Existing definitions of personalized medicine disagree about which questions, methods, and actions fall within its domain. Some define the term narrowly, referring to the use of a diagnostic test to predict drug response, thereby clarifying whether or not a patient will benefit from that drug. An example of this combination is the HER2/neu test to predict the effectiveness of trastuzumab in breast cancer. Many who adopt this definition associate the concept of personalized medicine with fields such as genetics, genomics, and other types of "-omics." In contrast, others view personalized medicine as a concept that has always existed, because medicine has always considered the needs of the individual. One definition of personalized medicine that accommodates both interpretations is "the use of combined knowledge (genetic or otherwise) about a person to predict disease susceptibility, disease prognosis, or treatment response and thereby improve that person's health." This predictive ability can increase over time through innovations in various technologies, resulting in further improvements in health outcomes. Moreover, these developments can lead to a better understanding of the underlying causes of disease, which can eventually lead to breakthroughs in the treatment of individual patients. In that sense, a truly personalized form of medicine can also be seen as an ideal, a goal that will be achieved only after multiple advances in science. Although the term personalized medicine was rechristened somewhat recently, our ability to personalize medicine will continue to advance in unimaginable ways as we come to learn more about the heterogeneity that exists among individuals and diseases.

[1]  M. Dowsett,et al.  Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. , 2005, The New England journal of medicine.

[2]  R. Ledley,et al.  Reasoning foundations of medical diagnosis. , 1991, M.D. computing : computers in medical practice.

[3]  A. Issa,et al.  Cost effectiveness of gene expression profiling for early stage breast cancer , 2012, Cancer.

[4]  Ginny Allain,et al.  Personalized medicine. , 2012, MLO: medical laboratory observer.

[5]  K. Anderson,et al.  Cardiovascular disease risk profiles. , 1991, American heart journal.

[6]  G. Lyman,et al.  Cost effectiveness of gene expression profiling for early stage breast cancer , 2012, Cancer.

[7]  J. Janssen,et al.  Application of cost-effectiveness analysis to demonstrate the potential value of companion diagnostics in chronic myeloid leukemia. , 2011, Pharmacogenomics.

[8]  Peter J Neumann,et al.  Personalized medicine: factors influencing reimbursement. , 2010, Health policy.

[9]  S. le Cessie,et al.  Loading and maintenance dose algorithms for phenprocoumon and acenocoumarol using patient characteristics and pharmacogenetic data. , 2011, European heart journal.

[10]  R. Altman,et al.  Estimation of the warfarin dose with clinical and pharmacogenetic data. , 2009, The New England journal of medicine.

[11]  M. Manns,et al.  Cost-effectiveness of truncated therapy for hepatitis C based on rapid virologic response. , 2012, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[12]  Ulrich Mansmann,et al.  Identification of a 24-gene prognostic signature that improves the European LeukemiaNet risk classification of acute myeloid leukemia: an international collaborative study. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  Z. Tezak,et al.  US FDA and personalized medicine: in vitro diagnostic regulatory perspective. , 2010, Personalized medicine.

[14]  W. Gibson Can personalized medicine survive? , 1971, Canadian family physician Medecin de famille canadien.

[15]  R S LEDLEY,et al.  Reasoning foundations of medical diagnosis; symbolic logic, probability, and value theory aid our understanding of how physicians reason. , 1959, Science.

[16]  Gibson Wm Can Personalized Medicine Survive , 1971 .

[17]  Mark R. Trusheim,et al.  Stratified medicine: strategic and economic implications of combining drugs and clinical biomarkers , 2007, Nature Reviews Drug Discovery.

[18]  J. Woodcock,et al.  The Prospects for “Personalized Medicine” in Drug Development and Drug Therapy , 2007, Clinical pharmacology and therapeutics.